BACKGROUND: MicroRNAs (miRNAs) are RNA molecules that are involved in the regulation of many cellular processes, including those related to human cancers. The aim of this study was to determine, as a proof of principle, whether specific candidate miRNAs could be detected in fine-needle aspirate (FNA) biopsies of pancreatic ductal adenocarcinoma (PDAC) and could accurately differentiate malignant from benign pancreatic tissues. METHODS: We used TaqMan(R) assays to quantify miRNA levels in FNA samples collected in RNARetain (n = 16) and compared the results with a training set consisting of frozen macrodissected pancreatic samples (n = 20). RESULTS: Quantitative reverse-transcription PCR analysis confirmed that miRNA levels are affected in PDAC FNAs and correlate well with the changes observed in the training set of frozen pancreatic samples. Analysis of the amounts produced for a few specific miRNAs enabled identification of PDAC samples. The combination of miR-196a and miR-217 biomarkers further improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis in the training set (P = 8.2 x 10(-10)), as well as segregate PDAC FNA samples from other FNA samples (P = 1.1 x 10(-5)). Furthermore, we showed that miR-196a production is likely specific to PDAC cells and that its incidence paralleled the progression of PDAC. CONCLUSIONS: To the best of our knowledge, this study is the first to evaluate the diagnostic potential of miRNAs in a clinical setting and has shown that miRNA analysis of pancreatic FNA biopsy samples can aid in the pathologic evaluation of suspicious cases and may provide a new strategy for improving the diagnosis of pancreatic diseases.
BACKGROUND: MicroRNAs (miRNAs) are RNA molecules that are involved in the regulation of many cellular processes, including those related to humancancers. The aim of this study was to determine, as a proof of principle, whether specific candidate miRNAs could be detected in fine-needle aspirate (FNA) biopsies of pancreatic ductal adenocarcinoma (PDAC) and could accurately differentiate malignant from benign pancreatic tissues. METHODS: We used TaqMan(R) assays to quantify miRNA levels in FNA samples collected in RNARetain (n = 16) and compared the results with a training set consisting of frozen macrodissected pancreatic samples (n = 20). RESULTS: Quantitative reverse-transcription PCR analysis confirmed that miRNA levels are affected in PDAC FNAs and correlate well with the changes observed in the training set of frozen pancreatic samples. Analysis of the amounts produced for a few specific miRNAs enabled identification of PDAC samples. The combination of miR-196a and miR-217 biomarkers further improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis in the training set (P = 8.2 x 10(-10)), as well as segregate PDAC FNA samples from other FNA samples (P = 1.1 x 10(-5)). Furthermore, we showed that miR-196a production is likely specific to PDAC cells and that its incidence paralleled the progression of PDAC. CONCLUSIONS: To the best of our knowledge, this study is the first to evaluate the diagnostic potential of miRNAs in a clinical setting and has shown that miRNA analysis of pancreatic FNA biopsy samples can aid in the pathologic evaluation of suspicious cases and may provide a new strategy for improving the diagnosis of pancreatic diseases.
Authors: D O'Toole; L Palazzo; R Arotçarena; A Dancour; A Aubert; P Hammel; J Amaris; P Ruszniewski Journal: Gastrointest Endosc Date: 2001-04 Impact factor: 9.427
Authors: J Lüttges; H Galehdari; V Bröcker; I Schwarte-Waldhoff; D Henne-Bruns; G Klöppel; W Schmiegel; S A Hahn Journal: Am J Pathol Date: 2001-05 Impact factor: 4.307
Authors: W Fraser Symmans; Mark Ayers; Edwin A Clark; James Stec; Kenneth R Hess; Nour Sneige; Thomas A Buchholz; Savitri Krishnamurthy; Nuhad K Ibrahim; Aman U Buzdar; Richard L Theriault; Marguerite F M Rosales; Eva S Thomas; Karin M Gwyn; Marjorie C Green; Abdul R Syed; Gabriel N Hortobagyi; Lajos Pusztai Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Mohamad A Eloubeidi; Darshana Jhala; David C Chhieng; Victor K Chen; Isam Eltoum; Selwyn Vickers; C Mel Wilcox; Nirag Jhala Journal: Cancer Date: 2003-10-25 Impact factor: 6.860
Authors: Ena Wang; Lance D Miller; Galen A Ohnmacht; Simone Mocellin; Ainhoa Perez-Diez; David Petersen; Yingdong Zhao; Richard Simon; John I Powell; Esther Asaki; H Richard Alexander; Paul H Duray; Meenhard Herlyn; Nicholas P Restifo; Edison T Liu; Steven A Rosenberg; Francesco M Marincola Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Christos Sotiriou; Trevor J Powles; Mitch Dowsett; Amir A Jazaeri; Andrew L Feldman; Laura Assersohn; Chandramouli Gadisetti; Steven K Libutti; Edison T Liu Journal: Breast Cancer Res Date: 2002-03-20 Impact factor: 6.466
Authors: Hanno Matthaei; Dennis Wylie; Maura B Lloyd; Marco Dal Molin; Jon Kemppainen; Skye C Mayo; Christopher L Wolfgang; Richard D Schulick; Laura Langfield; Bernard F Andruss; Alex T Adai; Ralph H Hruban; Anna E Szafranska-Schwarzbach; Anirban Maitra Journal: Clin Cancer Res Date: 2012-06-21 Impact factor: 12.531
Authors: Barbara Bournet; Marion Gayral; Jérôme Torrisani; Janick Selves; Pierre Cordelier; Louis Buscail Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Ji Kon Ryu; Hanno Matthaei; Marco Dal Molin; Seung-Mo Hong; Marcia I Canto; Richard D Schulick; Christopher Wolfgang; Michael G Goggins; Ralph H Hruban; Leslie Cope; Anirban Maitra Journal: Pancreatology Date: 2011-07-12 Impact factor: 3.996
Authors: Nicole M A White; Eman Fatoohi; Maged Metias; Klaus Jung; Carsten Stephan; George M Yousef Journal: Nat Rev Clin Oncol Date: 2010-11-02 Impact factor: 66.675